Insulin resistance and breast‐cancer risk

Abstract

Life‐style has a major influence on the incidence of breast cancer. To evaluate the effects of life‐style related metabolic‐endocrine factors on breast cancer risk we conducted a case‐control study comparing 223 women aged 38 to 75 years presenting with operable (stage I or II) breast cancer and 441 women of the same age having no breast cancer, who participated in a population‐based breast cancer screening program. Women reporting diabetes mellitus were excluded. Sera from 110 women of the same age group presenting with early stage melanoma, lymphoma or cervical cancer were used as a second ‘other‐cancer control group’. Serum levels of C‐peptide were significantly higher in early breast cancer cases compared to controls. The same was found for the ratios C‐peptide to glucose or C‐peptide to fructosamine, indicating insulin resistance. Sex hormone binding globulin was inversely, triglycerides and available estradiol were positively related to C‐peptide. Serum C‐peptide levels were related to body mass index (BMI), and to waist/hip ratio (WHR), in particular in controls. However, the relative increase of C‐peptide, C‐peptide to glucose or C‐peptide to fructosamine in cases was independent of BMI or WHR. The log relative risk was linearly related to the log C‐peptide levels. Relative risk according to quintiles, and adjusted for age, family history, BMI and WHR, for women at the 80% level was 2.9 as compared with those at the 20% level for C‐peptide. Elevated C‐peptide or C‐peptide to fructosamine values were not observed in the sera from women belonging to the ‘other‐cancer control group’. This study suggests that hyperinsulinemia with insulin resistance is a significant risk factor for breast cancer independent of general adiposity or body fat distribution. © 1992 Wiley‐Liss, Inc.